Argitalpenak (101) FRANCISCO BOLAS FERNÁNDEZ argitalpenak

2023

  1. Can amphotericin B and itraconazole be co-delivered orally? Tailoring oral fixed-dose combination coated granules for systemic mycoses

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 183, pp. 74-91

  2. Targeting lung macrophages for fungal and parasitic pulmonary infections with innovative amphotericin B dry powder inhalers

    International journal of pharmaceutics, Vol. 635, pp. 122788

2022

  1. Lentinula edodes extract increases goblet cell number and Muc2 expression in an intestinal inflammatory model of Trichinella spiralis infection

    Biomedicine and Pharmacotherapy, Vol. 150

  2. Self-assembling, supramolecular chemistry and pharmacology of amphotericin B: Poly-aggregates, oligomers and monomers

    Journal of Controlled Release, Vol. 341, pp. 716-732

2020

  1. (E)-piplartine isolated from piper pseudoarboreum, a lead compound against leishmaniasis

    Foods, Vol. 9, Núm. 9

  2. Evaluating the potential of ursolic acid as bioproduct for cutaneous and visceral leishmaniasis

    Molecules, Vol. 25, Núm. 6

  3. Nucleotides and AHCC Enhance Th1 Responses in Vitro in Leishmania-Stimulated/Infected Murine Cells

    Molecules, Vol. 25, Núm. 17

  4. Oral Fixed-Dose Combination Pharmaceutical Products: Industrial Manufacturing Versus Personalized 3D Printing

    Pharmaceutical Research, Vol. 37, Núm. 7

  5. Topical buparvaquone nano-enabled hydrogels for cutaneous leishmaniasis

    International Journal of Pharmaceutics, Vol. 588

  6. Transferosomes as nanocarriers for drugs across the skin: Quality by design from lab to industrial scale

    International Journal of Pharmaceutics, Vol. 573

  7. Ultradeformable Lipid Vesicles Localize Amphotericin B in the Dermis for the Treatment of Infectious Skin Diseases

    ACS Infectious Diseases, Vol. 6, Núm. 10, pp. 2647-2660

2019

  1. Repurposing butenafine as an oral nanomedicine for visceral leishmaniasis

    Pharmaceutics, Vol. 11, Núm. 7

2018

  1. In vitro activity of new N-benzyl-1H-benzimidazol-2-amine derivatives against cutaneous, mucocutaneous and visceral Leishmania species

    Experimental Parasitology, Vol. 184, pp. 82-89

  2. Intraperitoneal administration of the anti-IL-23 antibody prevents the establishment of intestinal nematodes in mice

    Scientific Reports, Vol. 8, Núm. 1

  3. Optimising the in vitro and in vivo performance of oral cocrystal formulations via spray coating

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 124, pp. 13-27

  4. Orally Bioavailable and Effective Buparvaquone Lipid-Based Nanomedicines for Visceral Leishmaniasis

    Molecular Pharmaceutics, Vol. 15, Núm. 7, pp. 2570-2583

  5. Systematic search for benzimidazole compounds and derivatives with antileishmanial effects

    Molecular Diversity, Vol. 22, Núm. 4, pp. 779-790

2017

  1. A novel LAMP assay for Trichuris spp. detection in stool and urine samples from a rodent model

    XX Congreso de la Sociedad Española de Parasitología (SOCEPA)

  2. Engineering oral and parenteral amorphous amphotericin B formulations against experimental Trypanosoma cruzi infections

    Molecular Pharmaceutics, Vol. 14, Núm. 4, pp. 1095-1106

  3. Leishmaniasis in the major endemic region of Plurinational State of Bolivia: Species identification, phylogeography and drug susceptibility implications

    Acta Tropica, Vol. 176, pp. 150-161